Format

Send to

Choose Destination
Saudi Pharm J. 2018 Dec;26(8):1089-1097. doi: 10.1016/j.jsps.2018.05.019. Epub 2018 May 31.

Identification and characterization of a novel antimicrobial peptide compound produced by Bacillus megaterium strain isolated from oral microflora.

Author information

1
Faculty of Science, Umm Al-Qura University, Makkah, Saudi Arabia.
2
Faculty of Science, Al-Azhar University, Cairo, Egypt.
3
College of Dentistry, Umm Al-Qura University, Makkah, Saudi Arabia.
4
Pediatric Dentistry and Oral Health Department, Faculty of Dental Medicine, Al-Azhar University, Cairo, Egypt.
5
Preventive Dentistry Dept., College of Dentistry, Umm Al-Qura University, Makkah, Saudi Arabia.
6
Pharmaceutics and Industrial Pharmacy Dept., Faculty of Pharmacy, Minia University, Minia, Egypt.
7
Pharmaceutics Dept., Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
8
Pharmaceutical Chemistry Dept., Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
9
Department of Biology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
10
Faculty of Science, Al-Baha University, Baha, Saudi Arabia.

Abstract

In recent years, the decreased efficacy of existing antibiotics toward management of emergent drug-resistant strains has necessitated the search for novel antibiotics from natural products. In this regard, Bacillus sp is well known for producing variety of secondary metabolites of potential use. Therefore, we performed an investigation to isolate and identify Bacillus sp from oral cavity for production of novel antimicrobial compounds. We extracted, purified, and identified a novel bioactive compound by B. megaterium (KC246043.1). The optimal production of compound was observed on de Man Rogosa and Sharpe broth by incubating at 37 °C, and pH 7.0 for 4 days. The bioactive compound was extracted by using n-butanol (2:1 v/v), purified on TLC plates with detection at Rf 7.8 cm; further characterized and identified as a cyclic ploypeptide sharing structural similarity with bacitracin. Minimum inhibitory concentration of bioactive compound was found to be 0.25, 0.5, 1.0, 3.125 and 6.25 μg/ml against Micrococcus luteus ATCC10240, Salmonella typhi ATCC19430, Escherichia coli ATCC35218. Pseudomonas aeruginosa ATCC27853 and Staphylococcus aureus ATCC25923 respectively, with no activity against Candida albicans ATCC10231. Our findings have revealed a novel cyclic peptide compound from B. megaterium with broad spectrum antimicrobial activity against both Gram positive and Gram negative bacteria.

KEYWORDS:

Antibacterial; Bacillus megaterium; Bacitracin; Drug discovery; Peptide antibiotics

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center